GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Johnson & Johnson (BUE:JNJ) » Definitions » Cyclically Adjusted PS Ratio

Johnson & Johnson (BUE:JNJ) Cyclically Adjusted PS Ratio : 4.71 (As of Apr. 29, 2024)


View and export this data going back to . Start your Free Trial

What is Johnson & Johnson Cyclically Adjusted PS Ratio?

As of today (2024-04-29), Johnson & Johnson's current share price is ARS10584.00. Johnson & Johnson's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was ARS2,246.22. Johnson & Johnson's Cyclically Adjusted PS Ratio for today is 4.71.

The historical rank and industry rank for Johnson & Johnson's Cyclically Adjusted PS Ratio or its related term are showing as below:

BUE:JNJ' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 3.74   Med: 4.81   Max: 5.9
Current: 4.21

During the past years, Johnson & Johnson's highest Cyclically Adjusted PS Ratio was 5.90. The lowest was 3.74. And the median was 4.81.

BUE:JNJ's Cyclically Adjusted PS Ratio is ranked worse than
75.78% of 739 companies
in the Drug Manufacturers industry
Industry Median: 2.09 vs BUE:JNJ: 4.21

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Johnson & Johnson's adjusted revenue per share data for the three months ended in Dec. 2023 was ARS635.321. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ARS2,246.22 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Johnson & Johnson Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Johnson & Johnson's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Johnson & Johnson Cyclically Adjusted PS Ratio Chart

Johnson & Johnson Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.21 5.46 5.52 5.32 4.51

Johnson & Johnson Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.57 4.80 4.47 4.51 -

Competitive Comparison of Johnson & Johnson's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - General subindustry, Johnson & Johnson's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Johnson & Johnson's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Johnson & Johnson's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Johnson & Johnson's Cyclically Adjusted PS Ratio falls into.



Johnson & Johnson Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Johnson & Johnson's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=10584.00/2246.22
=4.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Johnson & Johnson's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Johnson & Johnson's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=635.321/129.4194*129.4194
=635.321

Current CPI (Dec. 2023) = 129.4194.

Johnson & Johnson Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 9.993 99.695 12.973
201406 11.022 100.560 14.185
201409 10.856 100.428 13.990
201412 10.985 99.070 14.350
201503 10.845 99.621 14.089
201506 11.495 100.684 14.776
201509 11.456 100.392 14.768
201512 16.465 99.792 21.353
201603 18.212 100.470 23.460
201606 18.494 101.688 23.537
201609 19.086 101.861 24.250
201612 20.755 101.863 26.370
201703 19.887 102.862 25.021
201706 22.660 103.349 28.376
201709 25.155 104.136 31.263
201712 28.127 104.011 34.998
201803 29.515 105.290 36.279
201806 38.180 106.317 46.476
201809 54.904 106.507 66.715
201812 56.416 105.998 68.882
201903 57.998 107.251 69.986
201906 68.261 108.070 81.746
201909 86.841 108.329 103.748
201912 92.792 108.420 110.764
202003 96.164 108.902 114.282
202006 94.187 108.767 112.071
202009 117.269 109.815 138.204
202012 136.984 109.897 161.319
202103 150.460 111.754 174.243
202106 165.320 114.631 186.647
202109 170.622 115.734 190.797
202112 73.840 117.630 81.241
202203 188.659 121.301 201.286
202206 216.674 125.017 224.304
202209 208.804 125.227 215.795
202212 251.990 125.222 260.437
202303 375.250 127.348 381.354
202306 466.710 128.729 469.214
202309 586.091 129.860 584.105
202312 635.321 129.419 635.321

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Johnson & Johnson  (BUE:JNJ) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Johnson & Johnson Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Johnson & Johnson's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Johnson & Johnson (BUE:JNJ) Business Description

Address
One Johnson and Johnson Plaza, New Brunswick, NJ, USA, 08933
Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.

Johnson & Johnson (BUE:JNJ) Headlines